Abstract | OBJECTIVE: DESIGN: A prospective, multicenter, pilot, randomized controlled trial. SETTING: A network of 20 multidisciplinary ICUs. PATIENTS: INTERVENTIONS: MEASUREMENTS AND MAIN RESULTS: From 1,874 screened patients with acute respiratory distress syndrome, 200 were randomized: 99 to open lung approach and 101 to Acute Respiratory Distress Syndrome network protocol. Main outcome measures were 60-day and ICU mortalities, and ventilator-free days. Mortality at day-60 (29% open lung approach vs. 33% Acute Respiratory Distress Syndrome Network protocol, p = 0.18, log rank test), ICU mortality (25% open lung approach vs. 30% Acute Respiratory Distress Syndrome network protocol, p = 0.53 Fisher's exact test), and ventilator-free days (8 [0-20] open lung approach vs. 7 [0-20] d Acute Respiratory Distress Syndrome network protocol, p = 0.53 Wilcoxon rank test) were not significantly different. Airway driving pressure (plateau pressure - positive end-expiratory pressure) and PaO2/FIO2 improved significantly at 24, 48 and 72 hours in patients in open lung approach compared with patients in Acute Respiratory Distress Syndrome network protocol. Barotrauma rate was similar in both groups. CONCLUSIONS:
|
Authors | Robert M Kacmarek, Jesús Villar, Demet Sulemanji, Raquel Montiel, Carlos Ferrando, Jesús Blanco, Younsuck Koh, Juan Alfonso Soler, Domingo Martínez, Marianela Hernández, Mauro Tucci, Joao Batista Borges, Santiago Lubillo, Arnoldo Santos, Juan B Araujo, Marcelo B P Amato, Fernando Suárez-Sipmann, Open Lung Approach Network |
Journal | Critical care medicine
(Crit Care Med)
Vol. 44
Issue 1
Pg. 32-42
(Jan 2016)
ISSN: 1530-0293 [Electronic] United States |
PMID | 26672923
(Publication Type: Journal Article, Multicenter Study, Randomized Controlled Trial)
|
Topics |
- Female
- Humans
- Male
- Middle Aged
- Pilot Projects
- Prospective Studies
- Respiration, Artificial
(methods)
- Respiratory Distress Syndrome
(mortality, therapy)
- Time Factors
|
|
Join CureHunter, for free Research Interface BASIC access!
Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease.
Find out why thousands of doctors, pharma researchers and patient activists
around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!
|